Peer Review reports
From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Original Submission | ||
---|---|---|
29 Nov 2020 | Submitted | Original manuscript |
18 Jan 2021 | Reviewed | Reviewer Report |
25 Jan 2021 | Reviewed | Reviewer Report |
16 Mar 2021 | Author responded | Author comments - Zahra Mirzaasgari |
Resubmission - Version 2 | ||
16 Mar 2021 | Submitted | Manuscript version 2 |
3 Apr 2021 | Reviewed | Reviewer Report |
22 Apr 2021 | Author responded | Author comments - Zahra Mirzaasgari |
Resubmission - Version 3 | ||
22 Apr 2021 | Submitted | Manuscript version 3 |
23 Apr 2021 | Reviewed | Reviewer Report |
Resubmission - Version 4 | ||
Submitted | Manuscript version 4 | |
Publishing | ||
26 Apr 2021 | Editorially accepted | |
1 May 2021 | Article published | 10.1186/s12883-021-02218-4 |
You can find further information about peer review here.